Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
New Journey Health Technology Group Co.,LTD (002219.SZ)
CNY2.02
+0.02 (+1.00%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
Fortune Financial Center 100020
Beijing, CN
Beijing, CN
CEO
Liu Jun
Website
njhtg.com
IPO
2008-03-06
ISIN CNE1000009R5
Description
This company maintains a diverse business portfolio, encompassing the provision of medical services, pharmaceutical manufacturing, and the distribution of daily chemical and wellness products. Its pharmaceutical production includes various dosage forms such as tablets, syrups, capsules, mixtures, and pills. The enterprise was established on September 30, 2001, with its primary office situated in Beijing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY2.02
+0.02 (+1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
84M
Beta
0.30
Float Shares
2.12B
Free Float %
61.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.40% | -0.91% | -7.26% | -15.56% | -6.87% | +1.88% | -8.82% | -54.32% | -39.72% | -85.44% | +2.36% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.02
DCF (Unlevered)
0.43
-78.6%
DCF (Levered)
0.47
-76.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
0.63
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
1 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-19.6% Q1'26: -9.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-73.1% Q1'26: -19.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-4.2% Q1'26: -10.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.6% Q1'26: +8.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.9% Q1'26: +4.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.1% Q1'26: -0.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.64× Q1'26: 9.73× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.84B
est: 2.39B (+60.4%)
|
3.68B
est: 2.51B (+46.8%)
|
1.44B
est.
|
3.02B
est: 1.80B (+68.0%)
|
3.16B
est: 3.42B (-7.6%)
|
3.91B
est: 3.42B (+14.5%)
|
3.80B
est: 4.10B (-7.3%)
|
3.05B
est: 3.34B (-8.6%)
|
3.39B
3.39B – 3.39B
+1.5% YoY
|
3.78B
3.78B – 3.78B
+11.6% YoY
|
4.19B
4.19B – 4.19B
+10.9% YoY
|
| EBITDA |
-687.66M
est: 244.17M (-381.6%)
|
-1.95B
est: 256.15M (-862.7%)
|
146.58M
est.
|
35.30M
est: 183.22M (-80.7%)
|
487.44M
est: 348.94M (+39.7%)
|
342.44M
est: 348.94M (-1.9%)
|
451.67M
est: 412.98M (+9.4%)
|
401.71M
est: 336.44M (+19.4%)
|
341.46M
341.46M – 341.46M
+1.5% YoY
|
380.96M
380.96M – 380.96M
+11.6% YoY
|
422.44M
422.44M – 422.44M
+10.9% YoY
|
| EBIT |
-918.06M
est: 120.07M (-864.6%)
|
-2.09B
est: 125.96M (-1,757.8%)
|
72.08M
est.
|
-127.54M
est: 90.10M (-241.6%)
|
331.50M
est: 171.60M (+93.2%)
|
134.62M
est: 171.60M (-21.5%)
|
291.95M
est: 196.54M (+48.5%)
|
201.39M
est: 160.11M (+25.8%)
|
162.50M
162.50M – 162.50M
+1.5% YoY
|
181.30M
181.30M – 181.30M
+11.6% YoY
|
201.04M
201.04M – 201.04M
+10.9% YoY
|
| Net Income |
-1.42B
|
-2.52B
|
1.09B
est.
|
-371.43M
est: 1.32B (-128.2%)
|
156.12M
est: 32.88M (+374.8%)
|
28.97M
est: 32.88M (-11.9%)
|
114.77M
est: 98.75M (+16.2%)
|
30.94M
est: 65.84M (-53.0%)
|
65.84M
65.84M – 65.84M
+0.0% YoY
|
98.75M
98.75M – 98.75M
+50.0% YoY
|
98.75M
98.75M – 98.75M
+0.0% YoY
|
| SGA |
756.42M
est: 520.50M (+45.3%)
|
833.72M
est: 546.04M (+52.7%)
|
312.47M
est.
|
714.71M
est: 390.59M (+83.0%)
|
687.73M
est: 743.86M (-7.5%)
|
874.74M
est: 743.86M (+17.6%)
|
805.16M
est: 787.00M (+2.3%)
|
214.55M
est: 641.15M (-66.5%)
|
650.71M
650.71M – 650.71M
+1.5% YoY
|
725.99M
725.99M – 725.99M
+11.6% YoY
|
805.04M
805.04M – 805.04M
+10.9% YoY
|
| EPS |
-0.76
|
-1.35
|
0.33
est.
|
-0.20
est: 0.40 (-150.0%)
|
0.05
est: 0.01 (+378.0%)
|
0.01
est: 0.01 (-11.0%)
|
0.03
est: 0.03 (+16.3%)
|
0.01
est: 0.02 (-53.0%)
|
0.02
0.02 – 0.02
+0.0% YoY
|
0.03
0.03 – 0.03
+50.0% YoY
|
0.03
0.03 – 0.03
+0.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-581.84M
OE per share TTM
-0.17
Owner's Yield
-7.97%
Maintenance CapEx ratio
586.00%
Maint CapEx / Avg PPE
75.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 17 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 73.4K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 301.6K | 0.06% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 155.1K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 71.1K | 0.29% |
| 5 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 17.8K | 0.26% |
| 6 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 7.9K | 0.48% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 880.1K | 0.06% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 49.9K | 0.28% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 15.3K | 0.10% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.06M | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
22.1K
Shares Outstanding
3.45B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chen Nie | Vice President | — | male |
| Dian Zhu | Vice President | — | male |
| Lihua Song | Senior Vice President & Non-Independent Director | — | female |
| Liu Jun | Financial Director, Accounting Supervisor & Chief Financial Officer | — | male |
| Xu Xu | Vice President & Secretary of the Board of Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002219.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
